Goldman Sachs Raises PT on Abbvie (ABBV) to $52 StreetInsider.com (subscription) For example, key pipeline assets in Hep C, elagolix and daclizumab could generate over $5.5 bn at peak (exhibit 1) while we have only $3.3 bn in our total 2020 pipeline estimates. This does not include several products which are expected to enter Phase ... UPDATE: BMO Capital Raises PT on AbbVie Following 1Q13 Earnings Call |
